B-intervention	0	10	Carvedilol
O	11	14	for
O	15	25	Prevention
O	26	28	of
B-condition	29	41	Chemotherapy
I-condition	41	42	-
I-condition	42	49	Related
I-condition	50	64	Cardiotoxicity
O	64	65	:
O	66	69	The
O	70	75	CECCY
O	76	81	Trial
O	81	82	.

O	83	96	Anthracycline
O	97	98	(
O	98	101	ANT
O	101	102	)
O	103	115	chemotherapy
O	116	118	is
O	119	129	associated
O	130	134	with
O	135	149	cardiotoxicity
O	149	150	.

O	151	161	Prevention
O	162	166	with
O	167	168	β
O	168	169	-
O	169	177	blockers
O	178	185	remains
O	186	199	controversial
O	199	200	.

O	201	205	This
O	206	217	prospective
O	217	218	,
O	219	229	randomized
O	229	230	,
O	231	237	double
O	237	238	-
O	238	243	blind
O	243	244	,
O	245	252	placebo
O	252	253	-
O	253	263	controlled
O	264	269	study
O	270	276	sought
O	277	279	to
O	280	288	evaluate
O	289	292	the
O	293	297	role
O	298	300	of
O	301	311	carvedilol
O	312	314	in
O	315	325	preventing
O	326	329	ANT
O	330	344	cardiotoxicity
O	344	345	.

O	346	349	The
O	350	357	authors
O	358	368	randomized
B-total-participants	369	372	200
B-eligibility	373	381	patients
I-eligibility	382	386	with
I-eligibility	387	391	HER2
I-eligibility	391	392	-
I-eligibility	392	400	negative
I-eligibility	401	407	breast
I-eligibility	408	414	cancer
I-eligibility	415	420	tumor
I-eligibility	421	427	status
I-eligibility	428	431	and
I-eligibility	432	438	normal
I-eligibility	439	443	left
I-eligibility	444	455	ventricular
I-eligibility	456	464	ejection
I-eligibility	465	473	fraction
I-eligibility	474	475	(
I-eligibility	475	479	LVEF
I-eligibility	479	480	)
I-eligibility	481	489	referred
I-eligibility	490	493	for
I-eligibility	494	497	ANT
I-eligibility	498	499	(
I-eligibility	499	502	240
I-eligibility	503	505	mg
I-eligibility	505	506	/
I-eligibility	506	508	m2
I-eligibility	508	509	)
O	510	512	to
O	513	520	receive
O	521	531	carvedilol
O	532	534	or
B-control	535	542	placebo
O	543	548	until
O	549	561	chemotherapy
O	562	572	completion
O	572	573	.

O	574	577	The
O	578	585	primary
O	586	594	endpoint
O	595	598	was
B-outcome-Measure	599	609	prevention
I-outcome-Measure	610	612	of
I-outcome-Measure	613	614	a
I-outcome-Measure	615	616	≥
I-outcome-Measure	616	618	10
I-outcome-Measure	618	619	%
I-outcome-Measure	620	629	reduction
I-outcome-Measure	630	632	in
I-outcome-Measure	633	637	LVEF
I-outcome-Measure	638	640	at
I-outcome-Measure	641	642	6
I-outcome-Measure	643	649	months
O	649	650	.

O	651	660	Secondary
O	661	669	outcomes
O	670	674	were
B-outcome-Measure	675	682	effects
I-outcome-Measure	683	685	of
I-outcome-Measure	686	696	carvedilol
I-outcome-Measure	697	699	on
I-outcome-Measure	700	708	troponin
I-outcome-Measure	709	710	I
O	710	711	,
B-outcome-Measure	712	713	B
I-outcome-Measure	713	714	-
I-outcome-Measure	714	718	type
I-outcome-Measure	719	730	natriuretic
I-outcome-Measure	731	738	peptide
O	738	739	,
O	740	743	and
B-outcome-Measure	744	753	diastolic
I-outcome-Measure	754	765	dysfunction
O	765	766	.

B-outcome	767	774	Primary
I-outcome	775	783	endpoint
O	784	792	occurred
O	793	795	in
B-iv-bin-abs	796	798	14
O	799	807	patients
O	808	809	(
B-iv-bin-percent	809	811	14
I-iv-bin-percent	811	812	.
I-iv-bin-percent	812	813	5
I-iv-bin-percent	813	814	%
O	814	815	)
O	816	818	in
O	819	822	the
O	823	833	carvedilol
O	834	839	group
O	840	843	and
B-cv-bin-abs	844	846	13
O	847	855	patients
O	856	857	(
B-cv-bin-percent	857	859	13
I-cv-bin-percent	859	860	.
I-cv-bin-percent	860	861	5
I-cv-bin-percent	861	862	%
O	862	863	)
O	864	866	in
O	867	870	the
O	871	878	placebo
O	879	884	group
O	885	886	(
O	886	887	p
O	888	889	=
O	890	891	1
O	891	892	.
O	892	893	0
O	893	894	)
O	894	895	.

O	896	898	No
O	899	910	differences
O	911	913	in
B-outcome	914	921	changes
I-outcome	922	924	of
I-outcome	925	929	LVEF
I-outcome	930	932	or
I-outcome	933	934	B
I-outcome	934	935	-
I-outcome	935	939	type
I-outcome	940	951	natriuretic
I-outcome	952	959	peptide
O	960	964	were
O	965	970	noted
O	971	978	between
O	979	985	groups
O	985	986	.

O	987	988	A
O	989	1000	significant
O	1001	1011	difference
O	1012	1019	existed
O	1020	1027	between
O	1028	1034	groups
O	1035	1037	in
B-outcome	1038	1046	troponin
I-outcome	1047	1048	I
I-outcome	1049	1055	levels
O	1056	1060	over
O	1061	1065	time
O	1065	1066	,
O	1067	1071	with
O	1072	1077	lower
O	1078	1084	levels
O	1085	1087	in
O	1088	1091	the
O	1092	1102	carvedilol
O	1103	1108	group
O	1109	1110	(
O	1110	1111	p
O	1112	1113	=
O	1114	1115	0
O	1115	1116	.
O	1116	1119	003
O	1119	1120	)
O	1120	1121	.

O	1122	1134	Additionally
O	1134	1135	,
O	1136	1137	a
O	1138	1143	lower
B-outcome	1144	1153	incidence
I-outcome	1154	1156	of
I-outcome	1157	1166	diastolic
I-outcome	1167	1178	dysfunction
O	1179	1182	was
O	1183	1188	noted
O	1189	1191	in
O	1192	1195	the
O	1196	1206	carvedilol
O	1207	1212	group
O	1213	1214	(
O	1214	1215	p
O	1216	1217	=
O	1218	1219	0
O	1219	1220	.
O	1220	1223	039
O	1223	1224	)
O	1224	1225	.

O	1226	1227	A
O	1228	1242	nonsignificant
O	1243	1248	trend
O	1249	1255	toward
O	1256	1257	a
O	1258	1262	less
O	1262	1263	-
O	1263	1273	pronounced
O	1274	1282	increase
O	1283	1285	in
B-outcome	1286	1288	LV
I-outcome	1289	1292	end
I-outcome	1292	1293	-
I-outcome	1293	1302	diastolic
I-outcome	1303	1311	diameter
O	1312	1318	during
O	1319	1322	the
O	1323	1329	follow
O	1329	1330	-
O	1330	1332	up
O	1333	1336	was
O	1337	1342	noted
O	1343	1345	in
O	1346	1349	the
O	1350	1360	carvedilol
O	1361	1366	group
O	1367	1368	(
B-iv-cont-mean	1368	1370	44
I-iv-cont-mean	1370	1371	.
I-iv-cont-mean	1371	1372	1
O	1373	1374	±
B-iv-cont-sd	1375	1376	3
I-iv-cont-sd	1376	1377	.
I-iv-cont-sd	1377	1379	64
I-iv-cont-sd	1380	1382	mm
O	1383	1385	to
B-iv-cont-mean	1386	1388	45
I-iv-cont-mean	1388	1389	.
I-iv-cont-mean	1389	1390	2
O	1391	1392	±
B-iv-cont-sd	1393	1394	3
I-iv-cont-sd	1394	1395	.
I-iv-cont-sd	1395	1396	2
I-iv-cont-sd	1397	1399	mm
O	1400	1402	vs
O	1402	1403	.
B-cv-cont-mean	1404	1406	44
I-cv-cont-mean	1406	1407	.
I-cv-cont-mean	1407	1408	9
O	1409	1410	±
B-cv-cont-sd	1411	1412	3
I-cv-cont-sd	1412	1413	.
I-cv-cont-sd	1413	1414	6
I-cv-cont-sd	1415	1417	mm
O	1418	1420	to
B-cv-cont-mean	1421	1423	46
I-cv-cont-mean	1423	1424	.
I-cv-cont-mean	1424	1425	4
O	1426	1427	±
B-cv-cont-sd	1428	1429	4
I-cv-cont-sd	1429	1430	.
I-cv-cont-sd	1430	1431	0
I-cv-cont-sd	1432	1434	mm
O	1434	1435	;
O	1436	1437	p
O	1438	1439	=
O	1440	1441	0
O	1441	1442	.
O	1442	1445	057
O	1445	1446	)
O	1446	1447	.

O	1448	1450	In
O	1451	1455	this
O	1456	1463	largest
O	1464	1472	clinical
O	1473	1478	trial
O	1479	1481	of
O	1482	1483	β
O	1483	1484	-
O	1484	1492	blockers
O	1493	1496	for
O	1497	1507	prevention
O	1508	1510	of
O	1511	1525	cardiotoxicity
O	1526	1531	under
O	1532	1544	contemporary
O	1545	1548	ANT
O	1549	1555	dosage
O	1555	1556	,
O	1557	1560	the
O	1561	1568	authors
O	1569	1574	noted
O	1575	1576	a
O	1577	1579	13
O	1579	1580	.
O	1580	1581	5
O	1581	1582	%
O	1583	1585	to
O	1586	1588	14
O	1588	1589	.
O	1589	1590	5
O	1590	1591	%
B-outcome	1592	1601	incidence
I-outcome	1602	1604	of
I-outcome	1605	1619	cardiotoxicity
O	1619	1620	.

O	1621	1623	In
O	1624	1628	this
O	1629	1637	scenario
O	1637	1638	,
O	1639	1649	carvedilol
O	1650	1653	had
O	1654	1656	no
O	1657	1663	impact
O	1664	1666	on
O	1667	1670	the
O	1671	1680	incidence
O	1681	1683	of
O	1684	1689	early
O	1690	1695	onset
O	1696	1698	of
O	1699	1703	LVEF
O	1704	1713	reduction
O	1713	1714	.

O	1715	1722	However
O	1722	1723	,
O	1724	1727	the
O	1728	1731	use
O	1732	1734	of
O	1735	1745	carvedilol
O	1746	1754	resulted
O	1755	1757	in
O	1758	1759	a
O	1760	1771	significant
O	1772	1781	reduction
O	1782	1784	in
O	1785	1793	troponin
O	1794	1800	levels
O	1801	1804	and
O	1805	1814	diastolic
O	1815	1826	dysfunction
O	1826	1827	.

O	1828	1829	(
O	1829	1839	Carvedilol
O	1840	1846	Effect
O	1847	1849	in
O	1850	1860	Preventing
O	1861	1873	Chemotherapy
O	1873	1874	-
O	1874	1881	Induced
O	1882	1896	Cardiotoxicity
O	1897	1898	[
O	1898	1903	CECCY
O	1903	1904	]
O	1904	1905	;
O	1906	1917	NCT01724450
O	1917	1918	)
O	1918	1919	.
